American Association for Cancer Research

Table 1

Characteristics of study participants

Characteristic	Placebo (N = 53)	Pulmicort (N = 53)
Age, y
Median	58	55
Range	42–74	44–74
Sex, no. (%)
Male	39 (74)	38 (72)
Female	14 (26)	15 (28)
Smoking history, pack-years
Median	52	44
Range	30–93	27–115
Smoking status, no. (%)
Current smoker	44 (83)	39 (74)
Former smoker	9 (17)	14 (26)^*
Highest grade of dysplasia in baseline biopsy samples, no. (%)	41 (77)	46 (87)
Mild	12 (23)	7 (13)
Moderate/Severe	41 (77)	39 (74)
≥2 sites of dysplasia, no. (%)			5
10-year lung cancer risk (%)^†	(1–11)	(1–11)

Characteristic	Placebo (N = 53)	Pulmicort (N = 53)
Age, y
Median	58	55
Range	42–74	44–74
Sex, no. (%)
Male	39 (74)	38 (72)
Female	14 (26)	15 (28)
Smoking history, pack-years
Median	52	44
Range	30–93	27–115
Smoking status, no. (%)
Current smoker	44 (83)	39 (74)
Former smoker	9 (17)	14 (26)^*
Highest grade of dysplasia in baseline biopsy samples, no. (%)	41 (77)	46 (87)
Mild	12 (23)	7 (13)
Moderate/Severe	41 (77)	39 (74)
≥2 sites of dysplasia, no. (%)			5
10-year lung cancer risk (%)^†	(1–11)	(1–11)

The number of former smokers in the placebo group was not statistically significantly different from the number of former smokers in the Pulmicort group (P = 0.25; χ² test).

†

Risk assessment using algorithm reported by Bach et al. (27) assuming the current smokers stopped smoking at enrollment.

View Large

This Feature Is Available To Subscribers Only